Sensitization of cells and retroviruses to human serum by (αl-3) galactosyltransferase

[1]  F. Cosset,et al.  Retroviral retargeting by envelopes expressing an N-terminal binding domain , 1995, Journal of virology.

[2]  J. Fabre.  Nudging xenotransplantation towards humans , 1995, Nature Medicine.

[3]  J. Platt,et al.  Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury , 1995, Nature Medicine.

[4]  Y Takeuchi,et al.  Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell , 1994, Journal of virology.

[5]  K. Gustafsson,et al.  α1,3Galactosyltransferase: A Target for in vivo Genetic Manipulation in Xenotransplantation , 1994, Immunological reviews.

[6]  M. Sandrin,et al.  Galα(1,3)Gal, the Major Xenoantigen(s) Recognised in Pigs by Human Natural Antibodies , 1994, Immunological reviews.

[7]  U. Galili,et al.  Differential host-dependent expression of alpha-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model. , 1994, The Journal of general virology.

[8]  R. Oriol,et al.  CARBOHYDRATE ANTIGENS OF PIG TISSUES REACTING WITH HUMAN NATURAL ANTIBODIES AS POTENTIAL TARGETS FOR HYPERACUTE VASCULAR REJECTION IN PIG‐TO‐MAN ORGAN XENOTRANSPLANTATION1 , 1993, Transplantation.

[9]  M. Sandrin,et al.  Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Radic,et al.  One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. , 1993, Blood.

[11]  J. Griffiss,et al.  Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. , 1992, The Journal of clinical investigation.

[12]  O. Danos,et al.  Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses , 1992, Journal of virology.

[13]  U. Galili,et al.  Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Cummings,et al.  Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:beta-D-Gal(1,4)-D-GlcNAc alpha(1,3)-galactosyltransferase cDNA. , 1990, The Journal of biological chemistry.

[15]  J. Griffiss,et al.  Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora , 1988, Infection and immunity.

[16]  J. Levy,et al.  The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. , 1986, Virology.

[17]  R. Hirsch,et al.  Host modification of Sindbis virus sialic acid content influences alternative complement pathway activation and virus clearance. , 1981, Journal of immunology.

[18]  R. Kurth,et al.  Heterophil human antibodies recognize oncovirus envelope antigens: epidemiological parameters and immunological specificity of the reaction. , 1981, Virology.

[19]  M. Barbacid,et al.  Humans have antibodies capable of recognizing oncoviral glycoproteins: demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure to virus. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. Snyder,et al.  Specificity of human antibodies to oncovirus glycoproteins: recognition of antigen by natural antibodies directed against carbohydrate structures. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Müller-Eberhard,et al.  Lysis of oncornaviruses by human serum. Isolation of the viral complement (C1) receptor and identification as p15E , 1978, The Journal of experimental medicine.

[22]  R. Welsh.  Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement. , 1977, Journal of immunology.

[23]  F. Jensen,et al.  Inactivation of lysis of oncornaviruses by human serum. , 1976, Virology.

[24]  F. Jensen,et al.  Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway , 1976, The Journal of experimental medicine.

[25]  F. Jensen,et al.  Human serum lyses RNA tumour viruses , 1975, Nature.

[26]  J. Stocker,et al.  Human lymphocytotoxic and haemagglutinating activity against sheep and pig cells. , 1968, Lancet.

[27]  I. C. Almeida,et al.  Glycoconjugates of Trypanosoma cruzi: A 74 kD antigen of trypomastigotes specifically reacts with lytic anti‐α‐galactosyl antibodies from patients with chronic Chagas disease , 1993, Journal of clinical laboratory analysis.

[28]  M. Miwa,et al.  Human T-cell leukaemia virus is not lysed by human serum , 1984, Nature.